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ABSTRACT
Personalized tissue engineering and regenerative medicine (TERM) therapies propose patient-
oriented effective solutions, considering individual needs. Cell-based therapies, for example, may
benefit from cell sources that enable easier autologous set-ups or from recent developments on
IPS cells technologies towards effective personalized therapeutics. Furthermore, the customiza-
tion of scaffold materials to perfectly fit a patient’s tissue defect through rapid prototyping
technologies, also known as 3D printing, is now a reality. Nevertheless, the timing to expand
cells or to obtain functional in vitro tissue substitutes prior to implantation prevents advance-
ments towards routine use upon patient´s needs. Thus, personalized therapies also anticipate the
importance of creating off-the-shelf solutions to enable immediately available tissue engineered
products. This paper reviews the main recent developments and future challenges to enable
personalized TERM approaches and to bring these technologies closer to clinical applications.
ARTICLE HISTORY
Received 18 November 2015
Accepted 5 January 2016
Published online 2 February
2016
KEYWORDS
Cell therapies; cryo-banking;
cryopreservation;
customization; personalized
medicine; off-the-shelf;
tissue engineering;
translational platforms
Regenerative medicine approaches, including stem cells
therapies and tissue engineering, hold the potential to
revolutionize the management of numerous diseases
and trauma in the upcoming years. More recently, the
importance of personalized medicine in tissue engi-
neering and other cell-based therapies has been recog-
nized, envisioning the development of customized
approaches, where bioengineered products are tailored
to meet patient requirements and to improve patient
outcomes, including patient recovery time. This antici-
pates a significant decrease in the health care and
social co-lateral costs associated to ineffective or inade-
quate approaches (Figure 1).
In this review, recent developments toward persona-
lized tissue engineering and regenerative medicine
(TERM) approaches will be discussed, highlighting
those achieved through cell-based therapies using cell
sources with autologous potential and induced pluripo-
tent stem cell (iPSC) technologies and through custom-
made systems exploring rapid prototyping technolo-
gies and injectable systems to tailor patient-oriented
treatments. Moreover, emerging technologies and stra-
tegies for creating off-the-shelf solutions to enable
immediately available customized therapies will be
also addressed. Finally, the challenges and future per-
spectives toward the development of personalized
strategies will be discussed in the light of the possible
advances that these may enable for bringing TERM
technologies closer to routine clinical applications.
Paving the way for personalized regenerative
medicine
Cell-based therapies: stem cell sources
Several cell-based therapies, and tissue engineering
approaches, rely on the use of stem cells that are iso-
lated from human tissue samples, selected, expanded
and/or manipulated (e.g. differentiated into a specific
cell type) in vitro before being delivered via transplan-
tation to stimulate regeneration and enhancement of
functionality after damage, injury or degeneration of a
tissue or organ. A common methodology, applicable to
a certain extent as therapeutic agent, is the use of cells
previously isolated and harvested from autologous or
allogenic tissues.
Although mature resident cells from tissues seem to
be an obvious choice, in recent years, considerable
disadvantages that include local tissue morbidity, lim-
ited availability of tissues or organs for transplantation,
or even rejection and disease transmission risks, limited
the studies and progression toward clinical therapies.
Moreover, the invasive procedures to access the tissues
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to harvest these cells together with the low self-renewal
and proliferative capacities of tissue resident cells pur-
suit for alternative cell sources to overcome these
limitations.
Advances in biology and cell sciences lead to the
application of stem cells to stimulate regeneration
mechanisms. Stem cells can be obtained from practi-
cally all tissues in the body, from embryonic [1] to adult
tissue sources [2–5], allowing the development of sev-
eral exploratory approaches that can be more easily
employed in an autologous context aiming at persona-
lized cell therapies.
Embryonic stem cells
Embryonic stem cells (ESCs) derive from the inner cell
mass of the blastocysts, have a great capability to dif-
ferentiate into innumerous cell types, being therefore
designated pluripotent cells, and can be maintained
and expanded in vitro for long periods of time [6].
However, the risk of tumor formation, the immunologi-
cal compatibility of the transplanted cells, the ethical
considerations related to the manipulation of human
embryos and to the development of new research pro-
cedures also reflects their limitation in new research
advancements [6]. Nevertheless, clinical applications in
human patients refer the effectiveness of using ESCs in
the treatment of blindness-associated diseases as
Stargardt’s macular dystrophy and macular degenera-
tion [1].
Induced pluripotent stem cells
iPSCs hold great promise for personalized therapies as
iPSCs can be developed into any cell type in the body.
The reprogramming of somatic cells into iPSCs through
a small number of specific transcription factors like
Oct3/4, Sox2 and c-Myc has great potential for tissue-
specific regenerative therapies, avoiding ethical issues
associated to the use of ESCs [7]. Moreover, iPSCs can
recapitulate human disease with potential to repair or
replace diseased, injured or aged cells within the
human body, allowing the production of patient-speci-
fic cells and the development of cell replacement thera-
pies without the need for immunosuppressive drugs.
The generation of human iPSCs-derived retinal pigment
epithelium meets the clinical use requirements with
applicability in tissue replacement therapy of age-
related macular degeneration [8]. The combination of
human iPSC-derived cardiomyocytes, endothelial cells
and smooth muscle cells in a 3D fibrin patch also
demonstrated to improve heart function and metabo-
lism in a porcine model, without inducing ventricular
arrhythmias [9]. Furthermore, iPSC technology provides
a unique platform for the development of disease mod-
els and for screening the efficacy of new therapeutics
[10]. iPSCs-derived cardiac cells are currently being used
to assess the cardiotoxicity of drugs [11,12] and to
realize the pathogenesis of diseases such as myocardial
infarction, [13] diabetic cardiomyopathy [10] and right
ventricular dysplasia [13] envisioning primary therapeu-
tic uses.
However, studies on iPSCs are still limited and some
evidences suggest these cells may have low induction
efficiency and share tumorigenicity with ESCs. The fact
that iPSCs maintain an epigenetic memory of the cell
type of origin may also limit their clinical applica-
tion [14].
Figure 1. Schematic representation of the major areas of TERM strategies towards personalized medicine approaches, highlighting
the relevance of these strategies in the development of innovative and more efficient therapies.
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Adult stem cells
Adult stem cells are multipotent, and thus have a more
limited differentiation potential in comparison to ESCs.
Nevertheless, as endogenous mediators of regeneration
mechanisms, adult stem cells are considered an impor-
tant strategic tool for studies related to tissue and
organ regeneration with minimal ethical concerns.
Among stem cell sources, bone marrow, blood from
the umbilical cord and adipose tissue are the ones
mostly studied, stem cells from bone marrow, especially
hematopoietic stem cells and the umbilical cord are
more frequently referred in clinical therapies.
Bone marrow stem cells
Bone marrow-derived stem cells (BMSCs) have been
clinically used for over 40 years. They are formed by
heterogeneous cell populations of hematopoietic,
endothelial and mesenchymal stem cells (MSCs), being
considered one of the main stem cells sources for ther-
apeutic purposes [3]. In fact, their high differentiation
potential and low morbidity during the harvesting con-
stitute very significant advantages. However, there are
also some disadvantages such as the highly invasive
procedure for cell harvesting or the limitation of cell
availability that significantly decreases with aging [4,15].
In the last decades, several studies using BMSCs
verified a great potential for cell therapy applications,
including for the treatment of amyotrophic later sclero-
sis or ischemic cardiomyopathy, in which the transplan-
tation of MSCs derived from bone marrow was shown
to be a safe procedure and to improve the recovery and
survival of patients suffering from these conditions
[16–18].
Umbilical cord blood stem cells
Since the first umbilical cord blood stem cell transplan-
tation in 1988, umbilical cord blood has become an
important stem cell source not only due to its abundant
supply, painless collection and faster self-renewal, but
also due to its potential to differentiate into a variety of
cells, including osteoblasts, chondrocytes and adipo-
cytes, among others [19].
Besides the essential role of human cord blood stem
cells (hCBSCs) in the regeneration of blood and immune
system, treating blood diseases and inherited metabolic
disorders, new and emerging uses of these cells in
regenerative medicine have been investigated. For
instance, cell therapies using umbilical cord blood-
derived stem cells were shown to be clinically safe in
patients with decompensated liver cirrhosis and spinal
cord injury [20,21]. These studies suggest that hCBSC
can improve the function of the damaged tissues and
the quality of life in most patients [20,21].
Adipose-derived stem cells
Adipose tissue is an excellent source of stem cells, hold-
ing a big promise in regenerative therapies and for the
creation of a wide range of autologous substitutes [3].
Adipose tissue is very abundant and stem cells are rela-
tively easy to harvest [22] as compared to other sources
and can be expanded in vitro rapidly [3,23]. Besides,
adipose-derived stem cells (ASCs) exhibit a long-term
genetic stability and an important differentiation poten-
tial for several musculoskeletal tissues including bone,
cartilage and tendon [2,24]. Moreover, ASCs also exhibit
immunomodulatory functions from their interaction with
cells of both innate and adaptive immune systems.
Due to interest in the application of human adipose
for regenerative medicine, human ASCs (hASCs) have
been clinically explored. The autologous ASC transplan-
tation was demonstrated to be safe and feasible in the
treatment of ischemic cardiomyopathy and nonrevas-
cularizable critical limb ischemia [25,26].
Although cell-based therapies have shown successful
and promising outcomes in the management of a
handful of diseases and pathologies, there are plenty
of treatments and new strategies to be investigated,
especially for tissue and organ regeneration that may
not be completely fulfilled with current cell-based inter-
ventions and available medical procedures.
The versatile and successful clinical application of
stem cells in regenerative medicine and cell-based
therapies depends to some extent on the selection of
the stem cell source. In recent years, the search for a
universal cell source has highlighted the potential role
of allogenic cells to mediate regenerative actions avoid-
ing invasive harvesting procedures and time-demand-
ing methodologies to expand autologous cells.
Nevertheless, autologous cells from widely available
sources as adipose tissue, whose harvesting procedures
patient comply to renew the interest toward autolo-
gous clinical therapies. The use of autologous stem
cells is highly desirable once it avoids the problem of
biological incompatibilities and intraspecific variability,
with minimal ethical constrains and simplified transla-
tional regulatory procedures. Indeed, a total of 5223
clinical trials with stem cell from different tissue sources
are ongoing or were recently completed, as described
in Figure 2. These studies roughly represent 17% of all
clinical trials associated to cell therapies. Also, about
33% of the studies using stem cells correspond to
studies with autologous stem cells.
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The fundamental role of stem cells in tissue home-
ostasis and regeneration is not limited to stem cell
properties as self-renewal and multilineage differentia-
tion, but growing evidence suggests that paracrine
mechanisms and associated release of cytokines,
growth factors or microvesicles, often reported as
stem cell secretome, may constitute stem cells’ most
biologically significant role toward tissue regeneration.
Beyond the self-renewal capacity, proliferation and mul-
tilineage potential, stem cells secrete trophic paracrine
factors that mediate growth, differentiation, angiogenic,
anti-apoptotic or immunomodulatory actions, among
others, deeply influencing cell niche dynamics and reg-
ulating the therapeutic effect of stem cells.
Hemoderivatives and their potential role in cell-
based therapies
Another important issue concerning personalized cell-
based approaches relates to the use of humanized
media for preparing culture methodologies for clinical
studies. Traditionally, culture media protocols involve
the use of fetal bovine serum (FBS) as a growth supple-
ment [27]. The significant batch-to-batch variation [27],
a possible contamination with animal pathogens or
even the risk of xeno-immunization, has generated
numerous attempts to replace FBS by animal-free alter-
natives using commercial cocktails and hemoderivates,
such as platelet lysates (PLs) [15,28] and platelet-rich
plasma (PRP) [29,30]. In fact, human PLs have been
proven as an extremely effective cell culture additive
with potential for autologous approaches, minimizing
the risk of immunological reactions or infections [31]
and does not compromise the genomic stability or stem
cell differentiation [32,33]. Moreover, PLs are a pool of
growth factors available at physiological dosages with
potential for regenerative strategies. The implementa-
tion of human PLs into standard culture media proto-
cols represents a promising and safe tool for the
development of personalized cellular therapies [26,30].
As a hemoderivative, there are already established pro-
tocols that can facilitate PLs’ translation for clinical
Figure 2. Graphic representation of clinical trials involving stem cells. Data obtained from the website “clinicaltrials.gov” (accessed
date: 05 Nov 2015) using the keywords: “stem cells”, “bone marrow hematopoetic stem cells”, ”adipose stem cells” “umbilical cord
stem cells”, “induced pluripotent stem cells”, embryonic stem cells” and “bone marrow mesenchymal stem cells”. These studies were
also divided accordingly to the clinical phase. Phases 0 to 4 represent different categories of clinical studies, namely: Phase 0:
Exploratory study involving very limited human exposure to the drug (in this case stem cells represent the therapeutic agent), with
no therapeutic or diagnostic goals; Phase 1: studies that are usually conducted with healthy volunteers and that emphasize safety;
Phase 2: studies that gather preliminary data on effectiveness; Phase 3: studies that gather more information about safety and
effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs, Phase
4: studies occurring after FDA has approved a drug for marketing.
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application, including scale-up production with good
manufacturing practice compliance.
The widespread use of human hemoderivatives as
medium supplement may be also supported by studies
in which both PLs and PRPs have been used as ther-
apeutic agents [22,34–37]. Local application of PRP was
shown to reduce the pain and accelerate the functional
recovery of the repaired rotator cuff [34] and assist
cartilage repair [36], and that intra-articular injections
of PRP can also be useful for the treatment of early
degenerative articular pathology of the knee [35,37].
Moreover, a search for PRP and PLs in clinicaltrials.
gov (accessed 10 November 2015) resulted in 197 and
20 clinical studies, respectively, with particular inci-
dence to treat knee joint-associated diseases such as
osteoarthritis, tendinopathies and overall musculoskele-
tal diseases.
Customization of scaffold architectures
Tissue engineering strategies offer the possibility of
regenerating injured or degenerated tissues and organs
through the combination of cells within a 3D architec-
ture for tissue replacement. Traditionally, TE strategies
stand on three main pillars: cells, scaffolds and bioactive
molecules, mostly growth factors, often combined into
complex systems to recapitulate tissue requirements
and assist tissue regeneration aiming at full restoration
of tissue functionality. In these multidimensional sys-
tems, scaffolds act as cells and/or growth factor carrier/
vehicle, but also as mechanical support and conduit
until new tissue is formed. Therefore, the quest for
advanced and sophisticated scaffolds able to mimic
the complexity and functionality of the native tissues
to guide local cells and stimulate tissue regeneration is
increasingly important.
Scaffold fabrication
Mimicking tissues in organization, architecture and ulti-
mately in complexity is challenging especially considering
customization and personalized treatments to the precise
anatomical shape and dimensions of the tissue defect or
lesion of individual patients. Thus, scaffold fabrication
requires high-precision tools to allocate cell and bioma-
terials in a precise manner in order to generate a fully
functional 3D construct. Addictive manufacturing (AM)
technologies, also known as solid free-form fabrication,
rapid prototyping and 3D printing, employ a highly auto-
mated process that builds a 3D object through successive
deposition of layers of a material under computer control
and are especially advantageous for fabricating highly
controlled multifunctional 3D templates using fast, high
geometric precision with enhanced productivity and cost-
efficient computer-controlled equipment [38,39]. The
three most commonly used 3D printing technologies in
medical applications are fused deposition modeling
(FDM), thermal inkjet printing and selective laser sintering
(SLS) [40]. The methodology chosen will depend on the
biomaterials to form the 3D template as well as their
intrinsic characteristics and final application.
SLS has been used, for example, to fabricate a com-
posite scaffold of hydroxyapatite and polycaprolactone.
Results in rabbit femur defects suggest that 3D scaf-
folds seeded with bone marrow MSCs induced new
bone formation, showing large potential for orthopedic
and reconstructive applications [41]. In another work,
scaffolds of polyurethane (PU) inkjet printing produced
demonstrated good hierarchical structures, allowing a
good diffusion and ability to support fibroblast cell
attachment and growth, envisioning a possible applica-
tion in vascular tissue engineering [42]. Furthermore,
the viability of human fetal MSC was improved and
the extracellular matrix was homogeneously distributed
in polycaprolactone and tricalcium phosphate scaffolds
fabricated by FDM [43].
The use of 3D CT and other imaging techniques has
provided an automated way to replicate the 3D shape
of a target organ or tissue. For this, when the patient
goes for a presurgery CT scan or magnetic resonance
imaging, the scanning exam with the patient’s 3D volu-
metric information obtained from medical imaging can
be converted into a 3D digital model through a reverse
engineering process that perfectly meets the defect
dimensions and shape (Figure 3).
3D cell printing
3D printing has been investigated in medicine since the
early 2000s, being firstly used to make dental implants
and custom prosthetics. Since then, 3D printing systems
have been fabricated with increased complexity and
hierarchical organization in creative and spatial combi-
nations of cells and biomaterials (often in the form of
gels or fibers) for the development of biological sub-
stitutes providing enlightened possibilities of TERM.
Indeed, the capability of a 3D print with accurate
distribution of different elements, including structural
and cellular constituents, necessary to a functional tis-
sue replacement, in an organized way, and be able to
provide an optimized microenvironment to the growth
of 3D structured tissue, is one of the most exciting
prospects of bioprinting [44].
Despite the potential of this technology, printing of
living entities as cells is limited to specific techniques
and biomaterials. The printing process must be cyto-
compatible and operate in an aqueous environment
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[44,45], so as to fabricate structures capable of provid-
ing an optimized condition to the growth of a tissue or
organ [44]. Thus, natural-based hydrogel matrices are
an interesting option for cell printing to a wide range of
tissue substitute applications from liver to bone [46].
Bioinks for cell printing
Among the diverse technologies developed for TERM,
the 3D printing systems were revealed to be one of the
most attractive and powerful strategies for the devel-
opment of personalized constructs that mimic a real 3D
tissue or organ. However, the overall lack of suitable
bioinks for the generation of larger 3D constructs is
hampering both the progress in the field of 3D bioprint-
ing technologies and its translation toward clinical
application. From the polymeric materials point of
view, it remains a challenge to develop unique bioinks,
taking in account the required biological competence
and the physical requirements dictated by the biofab-
rication process.
A 3D bioprintable and cell-compatible bioink
should have tunable properties as stiffness, bioactive
motifs and suitable degradation rate so that the
printable solution could be self-supporting during
layer-by-layer fabrication and gelate rapidly on the
printing substrate [47]. Thus, they should exhibit
viscous fluid behavior within the printing head but
polymerize shortly after extrusion. This implies
decreased shear rates that are present inside a noz-
zle or orifice during biofabrication, followed by a
sharp increase in viscosity (resulting in a high-print-
ing fidelity) upon deposition.
Hydrogels are interesting materials to be used as
bioinks and to meet the bioprinting logistics as well
as be biocompatible assisting cell viability within a
highly hydrated environment [47,48]. Hyaluronic acid
and gelatin have been developed into a bioink system
to create liver constructs with high viability [47] while
PU and poly(ε-caprolactone) were applied to bioprint a
complex structure for engineering the muscle–tendon
unit [49].
Clinical application of 3D templates
The creation on demand of personalized scaffolds with
precise match to tissues or organs that require replace-
ment through transplantation envisions newer oppor-
tunities to produce specific and individually customized
scaffolds, with clinical applicability.
AM technologies allow the manipulation of biocom-
patible materials and the inclusion of cells and thera-
peutic agents within the 3D constructs in order to
enhance the biological response and patient follow-
Figure 3. Schematic representation of the customization process to design and fabricate personalized tissue engineering substitutes
oriented to patient individual requirements. The ability to accurately screen the lesion and recreate the defect in a 3D template with
living cues is a significant achievement for successful medical treatments of a wide range of injured or diseased tissues and organs.
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up. Moreover, it is widely accepted that the interface
between the tissue substitute and the host tissue
should be as intimate as possible.
Patient-specific medical implants have been digi-
tally designed to remake a facial bone defect using
SLS from polyamide 2200, which was shown to pre-
cisely fit into the defect [50]. Achieving the perfect fit
has several advantages, including the reduction time
of surgery, as the time spent in manual intraoperatory
modeling of the graft/scaffold is practically eliminated
and contributes to stable outcomes and to good heal-
ing [51]. In some cases, vascularization and biocompat-
ibility of the scaffold post implantation can be also
improved.
Other studies refer that computer-assisted reduction
technique combined with 3D printing was used to
fabricate a customized external fixator for treating tibial
fractures, showing good results on all three tibial frac-
tures under treatment [52].
3D printers have been also reported to materialize
artificial customized templates for a wide range of
human tissues, comprising heart tissue [53], spinal
disk, alveolar ridge augmentation and musculoskeletal
tissues, including bone defects [50,52,54–56], with clin-
ical studies evidencing promising outcomes with 3D
customized scaffolds as patient-tailored solutions.
Injectable hydrogels
While many applications benefit from innovative rapid
prototyping technologies, particularly where the scaf-
fold mechanical support is an essential feature, other
applications may benefit with the use of injectable
hydrogels (Figure 4).
Injectable hydrogels can be easily administrated via
minimal invasive procedures, filling the irregular shape
of the injury due to their pre-gelling fluidity [57,58],
thus providing a better integration of the hydrogel
with native tissue [59]. Indeed, this injectable metho-
dology can also deliver a large number of therapeutic
agents like drugs, growth factors and even cells, work-
ing like a promising injectable construct carrier
(Figure 5). Moreover, injectable matrices are a potential
system for cell delivery with impact in tissue regenera-
tion. This is because, unlike cells that are directly
injected at the injury site, cells within a hydrogel matrix
are protected from local biochemical influence and
from other cell-to-cell interaction immediately after
delivery. Since the hydrogel also provides some physi-
cal resistance to cellular mobility, cells are maintained
at the injection site for a longer period of time, which
can be advantageous to exert cell therapeutic action at
the desired location.
Figure 4. Graphical summary on the biomaterials and tools for 3D template fabrication aiming at personalized TERM approaches.
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However, the use of these injectable systems in bio-
medical applications is very recent and mostly limited to
in vitro studies. Investigations about cell-encapsulating
hydrogels have given encouraging results, indicating
that these systems can support the viability, proliferation
and chondrogenic differentiation of hASCs [60], with
significant potential as delivery systems for cell-based
cartilage therapies [59]. Furthermore, injectable systems
have also been used in the reconstruction of tissues lost
or affected by tumor resection or congenital defects [61].
Thus, injectable systems can pave new ways for
improved personalized therapeutics, oriented to fit the
patient’s defects and needs, using versatile matrices for
the delivery of cells and therapeutic factors to the site of
interest.
Cryobanking of cells, tissues, tissue-engineered
substitutes as off-the-shelf products
The process of developing tissue substitutes is fre-
quently labor intensive and requires long time spans
once it involves not only the fabrication of the scaffold
itself but often requires the isolation of cells, in vitro
expansion, and, depending on the strategy, seeding
and culture of cells in a construct before implantation
[62,63]. During this process, the patient is hampered
and waiting, which also implies social and health-care
providing costs. In order to overcome this problem, the
development of an effective preservation strategy
would generate a reliable source of ‘ready-to-use’
bioengineered products that can be immediately avail-
able for patient demands [62,64–66]. Thus, mid- to
long-term preservation and storage through cryobank-
ing of cells, tissues, tissue substitutes or other tridimen-
sional complex structures could be an attractive
approach to translate bioengineered products with
therapeutic value toward clinical applications.
The success of cell-based therapies requires not only
the guarantee of a continuous production of cells, but
also the identity and integrity maintenance as close as
possible to their native origin that can be severely
compromised in long-term in vitro cultures [67].
Traditional cryopreservation has been a routine prac-
tice and represents one of the oldest and the most
common storage process for cell lines by cooling to low
temperatures, typically to –196°C, using cryoprotectant
agents (CPAs) [68]. Other methods such as vitrification
[69] use ultra-fast cooling rates, and, more recently, mag-
netic cryopreservation [70–72] has also been explored to
address the challenge of completely eliminating the
cryoinjury, which affects to a certain extent survival and
functionality of retrieved cells.
CPAs are used to avoid the damage caused by the
ice formation during freezing and are classified as per-
meating or intracellular, such as dimethyl sulfoxide
(DMSO), ethylene glycol (EG) and nonpermeating or
intercellular compounds as polyvinylpyrrolidone (PVP),
polyethylene glycol, trehalose or sucrose. The first ones
penetrate the cell membrane, allowing the displace-
ment of the inner water from cell, avoiding the intra-
cellular ice formation, while intercellular CPA act from
the cell outside promoting a quick dehydration of the
cells, reducing the development of intracellular ice crys-
tals [67,73–75].
Figure 5. Schematic representation of methods using injectable systems with potential to be used as carriers of growth factors
(GFs), platelet lysates (PLs) or cells for tissue regeneration and to be stored and preserved for ready to use approaches.
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Growing knowledge in cell biology and recent devel-
opments in stem cells technologies have motivated the
creation of cryobanks of cells and stem cells making
available a wide collection of cell sources, including
bone marrow, cord blood and dental pulp, and, conse-
quently, off-the-shelf cells for transplant, while allowing
better timing for therapies. Cryopreserved stem cells
from bone marrow and cord blood have shown a ther-
apeutic effect on the treatment of multiple sclerosis
[76], and graft versus host disease [30], highlighting
the relevance of cryopreservation and banking for the
implantation and effectiveness of cell-based therapies
and as potential treatment for diseases that currently
have no cure. Clinical trials employing cryopreserved
stem cells are represented in Figure 6.
Although mammalian cell cryopreservation is consid-
ered a conventional and routine method worldwide,
with significant benefits accomplished in cell-based
therapies and in real clinical treatments, the challenge
for preserving an integrated tissue or construct, while
keeping cell features and the structural properties of
the supportive matrix, remains a challenge.
Despite the favorable outcomes of cryopreservation,
few studies have cryopreserved complex systems as
tissue-engineered constructs. Altogether, these studies,
which are compiled in Table 1, indicate that cryopre-
servation of tissue-engineered constructs is an effective
approach, allowing the maintenance, and in some
cases, the increment of the cellular recovery and viabi-
lity, regardless of the type of the 3D support; scaffolds,
microspheres, microcapsules, neurospheres, nanofi-
brous or even hydrogels.
Conclusion
This article reviewed the concepts and most recent
strategies of TERM toward personalized medicine
approaches with potential for developing innovative
and more efficient clinical therapies.
The knowledge on stem cell biology and associated
regenerative mechanisms has exponentially increased
in the last few years, bringing new hopes and new
options to the development of theranostic tools and
to effective treatments.
Nevertheless, the mid- to long-term preservation
platforms of cells as both disease and therapeutic
agents, tissues or tissue-like substitutes to be ready on
patient demand should be more deeply investigated to
explore better solutions for human cell-based therapies
that may also result in improved outcomes from phar-
macological and biomedical sciences.
Although 3D fabrication technologies have been
explored for decades, only in recent years have they
been considered to be appealing for the development
of 3D scaffold architectures for tissue engineering. Thus,
the customization of tissue-like substitutes using these
technologies is slowly arising but is expected to play a
role in future regenerative strategies.
Altogether, the proposed TERM strategies may have
an impact on the development of off-the-shelf tissue-
engineered products as well as in innovative persona-
lized tissue engineering therapies as alternative and
effective treatments for a wide range of diseases and
pathological conditions.
Expert commentary
Since the first concept of personalized medicine,
remarkable effort and progress toward the develop-
ment of technological outcomes have been accom-
plished in order to become a real and successful
model in the clinical field.
Figure 6. Graphic representation of clinical trials involving stem
cells. Data obtained from the website ‘clinicaltrials.gov’
(accessed date: 05 Nov 2015) using the keywords: ‘cryopre-
served stem cells’ The numbers within the graph represent the
number of clinical trials divided accordingly to the clinical
phase they were tested for a total of 55, corresponding to
1.05% of total clinical trials performed with stem cells. Phases
0 to 4 represent different categories of clinical studies, namely:
Phase 0: Exploratory study involving very limited human expo-
sure to the drug (in this case stem cells represent the ther-
apeutic agent), with no therapeutic or diagnostic goals; Phase
1: studies that are usually conducted with healthy volunteers
and that emphasize safety; Phase 2: studies that gather pre-
liminary data on effectiveness; Phase 3: studies that gather
more information about safety and effectiveness by studying
different populations and different dosages and by using the
drug in combination with other drugs, Phase 4: studies occur-
ring after FDA has approved a drug for marketing.
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Table 1. Cryopreservation of tissue-engineered constructs.
Scaffolding
material 3D template Cell type Cryopreservation protocol Major achievements Reference
Natural-based polymers
Alginate Gels
constructs
Human dental
pulp stem cells
Optimization of CPAs:
(1) DMEM + 10% EG;
(2) DMEM + 10% EG + 1.0 M sucrose
(3) DMEM + 10% EG + 1.0 M sucrose +
0.00025 M PVP
(4) DMEM + 10% EG + 1.0 M sucrose +
0.0005 M PVP
(5) DMEM + 10% EG + 1.0 M sucrose +
0.00075 M PVP
(6) DMEM + 40% EG +0.6 M sucrose
(7) DMEM + 10% FBS + 12% DMSO
The samples were stored at –80°C for 1, 7,
14, 21 and 28 days
DMEM supplemented with 10% EG, 1.0 M
sucrose and 0.00075 M PVP was the most
optimal CPA
No visual differences between the cell
viability of control (gel constructs without
cryopreservation-thawing process) and
cryopreserved gel was found
The cell characteristics were maintained
during encapsulation and cryopreservation
[63]
Neurospheres Brain cells
isolated Wistar
rat embryos
The cryopreservation media consisted of
serum-supplemented medium or serum-
free CryosStor-CS10 solution, both
containing 10% DMSO
The samples were stored in the liquid N2
for 1–2 weeks
Cryostor-CS10 solution enhances
cryopreservation and post-thawing
recovery for both nonencapsulated and
encapsulated neurospheres compared
with standard culture medium
[77]
Gel layer Neuroblastoma
N2a and colon
adenocarcinoma
Caco-2
Cryopreservation media:
(i) Standard medium: DMEM
supplemented with 10% heat-inactivated
FBS and 4.5 g/L glucose
(ii) Differentiation medium: DMEM+ 2%
FBS + 15 µM retinoic acid) supplemented
with 10% DMSO or CryoStor™ (BioLife
Solutions, Bothell, WA, USA)
Stored of the samples at –80°C for 1–2
weeks
Optimization of cryopreservation of
adherent cells in a fully differentiated state
The cryopreservation protocols facilitated
the reduction in batch-to-batch variability
and normalizing passage age
[78]
Microspheres Human MSCs Cryopreservation medium: 10% FCS and
DMSO at 5% and 10%
Cooling was manipulated accordingly to
three protocols:
Protocol 1: 2 steps slow cooling
Protocol 2: 3 steps slow cooling with
induced ice formation
Protocol 3: rapid 1 step freezing
Cryopreserved samples were kept at –196°
C for a month
The viability and metabolism of MSCs in
alginate microspheres was higher with
10% DMSO
The highest viabilities and metabolic rates
were obtained following the protocol 2.
After cryopreservation by protocol 2,
alginate microspheres with encapsulated
MSCs were capable of achieving
multilineage differentiation
[79]
Alginate-gelatin Cryogel
scaffolds
Human MSCs Cryopreservation with cryo-medium
containing 10% DMSO
The samples were stored at least 24 h in
liquid N2
Short culture times before
cryopreservation (0.5 and 2 h) are
preferable for adherent hMSCs than longer
times (24 h), showing higher viability and
recovery
[80]
APA Microcapsules Murine C2C12
myoblasts
DMSO concentrations (1%, 5%, 10%, 20%
and 30%)
The cells were stored in liquid N2 for 45
days
Freeze/thawed microencapsulated cells
using 10% DMSO showed the most
suitable features in terms of Epo release
[73]
Microcapsules MSCs genetically
modified (D1-
MSC)
CPA solutions combining DMSO, glycerol
and trehalose at different concentrations
(10% DMSO, 5% DMSO, 10% glycerol, 10%
trehalose, 5% trehalose + 5% DMSO, 5%
trehalose + 2.5% DMSO, 2.5% trehalose +
2.5% DMSO, 2.5% trehalose + 5% DMSO)
Cryovials were stored in liquid N2 for 2
weeks
10% DMSO represents the most suitable
solution for encapsulated MSCs
Nonpenetrating cryoprotectants such as
trehalose do not provide an appropriate
recovery for microencapsulated cells
[68]
Collagen Scaffold Mouse
fibroblasts
10% DMSO, 15% FBS and 0.4% antibiotics
The cells were stored in liquid N2 for 7–12
days
The cryopreservation of fibroblasts
immobilized within a PVF scaffold reveals
an efficient process. Besides, no negative
effects on cell recovery were observed
[81]
k-Carrageenan Hydrogels Human ASCs 10% DMSO in FBS
cells were stored in liquid N2 for 1 month
The hydrogels withstand the
cryopreservation maintaining their
structural integrity, while assisting cells
proliferation and chondrogenic potential
[64]
(Continued )
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Indeed, advancements in the complex and multidisci-
plinary strategies of TERM as cell-based therapies, drug and
cell delivery, as well as diagnosis and therapeutic tools, and
the development of 3D tailored tissue like substitutes, have
proved to be particularly interesting and promising for the
progress and exploitation of specialized therapies.
The significance of stem cell technologies in cell thera-
pies has been supported with clinical evidence. The selec-
tion of stem cell sources within an autologous context
would allow customized exploratory approaches with
potential to manage and treat several pathological condi-
tions. Although universal cells can also impact regenera-
tive medicine procedures, autologous sources will always
be privileged especially if there are easily accessible and
whose procedures patients comply with. Moreover, auto-
logous cells are fully compatible and liberated from
potential intraspecific restrictions.
Furthermore, the ability to generate multifunctional
systems and the customization of scaffold architectures
that perfectly fit to individual tissue defects using diag-
nostic scans or in situ delivery approaches, as injectable
hydrogels, enables revealing and powerful technologi-
cal tools that could revolutionize tissue regeneration
and tailoring health care to the individual patient.
Furthermore, personalized TERM strategies are
envisioned to evolve into more effective and success-
ful 3D templates with regenerative action. Advances
in 3D printing technologies will allow moving from
time-and labor-intensive fabrication technologies
into mass production of patient-oriented tissue and
organ substitutes, which will lead to a cost reduction
and an easier access to these technologies in medical
institutions. It is also expected that 3D bioprinting
advances will also influence the progress of imaging
technologies. This will result in improved equipment
with improved resolution and software to translate
tissue scans with a higher level of detail and informa-
tion into a virtual 3D model. Different properties of
complex biological systems could be accurately com-
bined, for instance, in the case of bone, the recon-
struction of structural and biomechanical properties
of cortical and trabecular bone, vascular vessels and
marrow within the same 3D template using multiple
biomaterials with different properties and cells or
growth factors. These outcomes will also benefit
interface tissues that require specific properties and
structures that fuse with the nearby tissue with com-
plementary functionality.
Table 1. (Continued).
Scaffolding
material 3D template Cell type Cryopreservation protocol Major achievements Reference
Silk Nanofibers Human MSCs
derived from
umbilical cord
Cryopreservation solutions:
(1) 10% DMSO, 50% FBS
(2) 40 mM trehalose
(3) 40 mM ectoin
(4) 40 mM trehalose and 40 mM ectoin
(5) 40 mM trehalose, 40 mM ectoin in
100 µg catalase
(6) 40 mM trehalose, 40 mM ectoin and
2.5% DMSO
(7) 40 mM trehalose, 40 mM ectoin, 2.5%
DMSO and 100 µg catalase as antioxidant
The samples were stored in liquid N2 for 7
days
Post-thaw cell proliferation rate was
higher in solutions containing trehalose/
ectoin with 2.5% DMSO than other
freezing solution
The addition of catalase used as
antioxidant has marginally increased cell
viability
[82]
Gelatin and
collagen/
elastin
Scaffolds Human
fibroblasts and
keratinocytes
Cryopreservation medium: 70% FAD
medium (F12: DMEM = 1:3), 10% FCS, 0.1
nM choleratoxin, 0.4 µg/mL
hydrocortisone, 50 µg/mL ascorbic acid
20% serum and 10% DMSO
The samples were stored 24 h in liquid N2
Cryopreservation has no negative
influence on vitality and differentiation
capacity of cultured constructs
[83]
Natural and synthetic polymeric blends
Polycaprolactone-
gelatin
Nanofibrous
scaffolds
Bone marrow-
derived porcine
MSCs
Vitrification strategy at low concentrations
of CPA (10% EG; 25% EG) and VS (40% EG
and 0.6 M sucrose)
The samples were stored in liquid N2 less
than 24 h
Vitrification approach is effective in
cryopreserving these TECs with high cell
viability while maintaining their integrity
[69]
Blend of starch
and poly
(caprolactone)
Fiber mesh
Scaffolds
Goat bone
marrow stem
cells
Cryopreservation medium of 10% DMSO
and FBS
The samples were stored in liquid N2
during 7 days
Maintenance of cell-viability and scaffolds
properties upon cryopreservation
[62]
ASC: adipose stem cells; APA: alginate-poly-L-lysine-alginate; CPA: cryoprotective agent; DMEM: Dulbecco Modified Eagle Medium; DMSO: dimethyl sulfoxide;
EG: ethylene glycol; FBS: fetal bovine serum; FCS: fetal calf serum; MSC: mesenchymal stem cells; N2: nitrogen; PVF: polyvinyl formal; VS: vitrification
solution; PVP: polyvinylpyrrolidone; TECs: tissue engineering constructs.
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The combination of all these developments with
the possibility to cryobank cells and more complex
systems as tissue-engineered constructs assists in
the translation of effective off-the-shelf strategies
involving custom-made products available upon
request.
Thus, the advances described are paving the way for
enhanced personalized treatments searching for inno-
vative and effective solutions to promote real tissue
regeneration meeting individual patient requirements
and needs.
Five-year view
Traditional medical practices often involve randomized
strategies to treat the masses, but this approach has
been revealed not to be always the best nor the most
cost effective. Individual needs should be considered
so that individual requirements can be successfully
fulfilled.
Within the next five years, it is expected that medical
practice will continue to evolve toward a better and
customized health care, with new strategies to be
developed so as to understand and improve current
therapeutic limitations, envisioning an increased effort
to tailor medical treatments to the individual character-
istics of each patient. Ongoing technological advances
in medicine will exponentially increase the level of
detail and information, bringing new knowledge and
the need to provide more precise diagnosis and pathol-
ogy management.
Scientific developments and clinical trials will help to
understand and guide personalized strategies toward a
successful clinical scenario. This pathway will be
assisted by the progress on stem cell technologies,
upscaling and mid- to long-term storage strategies so
that cell-based therapies can be widely available and
routinely applied in medical procedures. Since intraspe-
cific variations can interfere with follow-up and treat-
ment outcomes, autologous setups would be an ideal
option. With the iPSC technologies and stem cells from
selective sources, these variations could be minimized
or even eliminated and upscaling would become a
more tangible reality.
In order to facilitate translation and to provide off-the-
shelf products for patient on demand, preservation
methodologies are a critical step of the process.
Cryopreservation is a very promising methodology, and
new protocols that require no cryo-additives or preser-
vatives that may interfere with cell metabolism and
function should be investigated. Magnetic
cryopreservation may be a promising methodology to
be more deeply explored in future.
Recently, cell banks have been established world-
wide. Nevertheless, cryobanks of tissues, tissue-like sub-
stitutes as scaffolds or constructs, and other 3D
complex structures are still at their infancy, but are
expected to grow and facilitate tissue-like substitute
storage for clinical translation.
Tissue-engineered scaffolds and constructs have
been evolving with increased complexity, including
improved functionalities and hierarchical structural
motifs to recapitulate native tissue and to be recog-
nized by the cells. Thus, it is likely that not only the
scaffold will evolve but 3D biofabrication technologies
will also progress into more sophisticated tools to
accurately reproduce the detailed information from
medical scans into a 3D defect model to be built
upon request, through a simple and fast process with
state-of-the-art software. It is envisioned that, in a
relatively short period of time, this kind of technology
may become available in clean rooms close to the
surgical theater of some leading-edge hospitals to
assist grafting or replacement surgeries with custo-
mized 3D scaffolds.
Undoubtedly in five years time several hurdles will
remain, but surely several of these approaches and
technologies will be one step closer to meet the enthu-
siastic challenges of personalized medicine and revolu-
tionize the therapeutic field with custom-made
therapies and effective tailored treatments for a wide
range of pathologies.
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